China’s National Medical Products Administration approved Innovent Biologics’ Tabosun (ipilimumab N01, IBI-310) in combination with sintilimab as a neoadjuvant therapy for stage IIB–III resectable microsatellite instability‑high (MSI‑H) or mismatch repair deficient colon cancer, Innovent announced. The approval makes Tabosun the first domestically developed CTLA‑4 monoclonal antibody approved in China for this indication. Innovent positioned the combination to improve pathological response rates ahead of surgery in an MSI‑H patient population known to be responsive to immune‑checkpoint blockade. The regulatory win follows Innovent’s recent approvals in other oncology indications and supports the company’s growing oncology franchise. Clinicians and payors in China will now evaluate neoadjuvant immunotherapy pathways for resectable MSI‑H colorectal cancer, where tumor immunogenicity often predicts benefit. Innovent will need to demonstrate real‑world surgical and survival benefits to secure reimbursement and broad clinical uptake. The approval also underscores China’s accelerating capability to develop and greenlight domestically produced immunotherapies in high‑need cancer niches.